| 1 |
2022 |
Abdelrahman K. A. A. Salama, Marija V. Trkulja, Emilio Casanova, Iris Z. Uras. Targeted Protein Degradation: Clinical Advances in the Field of Oncology, International Journal of Molecular Sciences. 2022; 23: 15440.
https://doi.org/10.3390/ijms232315440 |
| 2 |
2023 |
Kristina Viktorsson, Thorsten Rieckmann, Maximilian Fleischmann, Markus Diefenhardt, Stephanie Hehlgans, Franz Rödel. Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy, Strahlentherapie und Onkologie. 2023;
https://doi.org/10.1007/s00066-023-02064-y |
| 3 |
2022 |
O. A. Koroleva, Yu. V. Dutikova, A. V. Trubnikov, F. A. Zenov, E. V. Manasova, A. A. Shtil, A. V. Kurkin. PROTAC: targeted drug strategy. Principles and limitations, Russian Chemical Bulletin. 2022; 71: 2310.
https://doi.org/10.1007/s11172-022-3659-z |
| 4 |
2023 |
Rodrigo Sánchez Bayona, Manuel Alva Bianchi. Luminal breast cancer treatment beyond cell cycle inhibitors, Revisiones en Cáncer. 2023;
https://doi.org/10.20960/revcancer.00027 |
| 5 |
2023 |
Carmen Avendaño, J. Carlos Menéndez. 2023; 637.
https://doi.org/10.1016/B978-0-12-818549-0.00012-1 |
| 6 |
2023 |
Lara J. Bou Malhab, Habiba Alsafar, Saleh Ibrahim, Mohamed Rahmani. PROTACs: Walking through hematological malignancies, Frontiers in Pharmacology. 2023; 14: 1086946.
https://doi.org/10.3389/fphar.2023.1086946 |
| 7 |
2023 |
Abhenil Mittal, Consolacion Molto Valiente, Faris Tamimi, Ilana Schlam, Sarah Sammons, Sara M. Tolaney, Paolo Tarantino. Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer, Cancers. 2023; 15: 2015.
https://doi.org/10.3390/cancers15072015 |
| 8 |
2022 |
Claudia J. Diehl, Alessio Ciulli. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders, Chemical Society Reviews. 2022; 51: 8216.
https://doi.org/10.1039/D2CS00387B |
| 9 |
2022 |
Zi Liu, Mingxing Hu, Yu Yang, Chenghao Du, Haoxuan Zhou, Chengyali Liu, Yuanwei Chen, Lei Fan, Hongqun Ma, Youling Gong, Yongmei Xie. An overview of PROTACs: a promising drug discovery paradigm, Molecular Biomedicine. 2022; 3: 46.
https://doi.org/10.1186/s43556-022-00112-0 |
| 10 |
2023 |
Miroslav Peřina, Márton A. Kiss, Gergő Mótyán, Eva Szczyrbová, Martin Eliáš, Vladimír Študent jr, Daniela Kurfürstová, Markéta Kovalová, Lukáš Mada, Jan Bouchal, Éva Frank, Radek Jorda. A-ring-fused pyrazoles of dihydrotestosterone targeting prostate cancer cells via the downregulation of the androgen receptor, European Journal of Medicinal Chemistry. 2023; 249: 115086115086.
https://doi.org/10.1016/j.ejmech.2023.115086 |
| 11 |
2023 |
Mayuri P Kannan, Sarojini Sreeraman, Chaitanya S Somala, Raja BS Kushwah, Saravanan K Mani, Vickram Sundaram, Anand Thirunavukarasou. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets, Future Medicinal Chemistry. 2023; 15: 867.
https://doi.org/10.4155/fmc-2023-0072 |
| 12 |
2022 |
Sinan Ma, Jianai Ji, Yuanyuan Tong, Yuxuan Zhu, Junwei Dou, Xian Zhang, Shicheng Xu, Tianbao Zhu, Xiaoli Xu, Qidong You, Zhengyu Jiang. Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope, Acta Pharmaceutica Sinica B. 2022; 12: 2990.
https://doi.org/10.1016/j.apsb.2022.02.022 |
| 13 |
2022 |
Hang Luo, Li Wu, Yujian He, Chong Qin, Xinjing Tang. Major Advances in Emerging Degrader Technologies, Frontiers in Cell and Developmental Biology. 2022; 10: 921958.
https://doi.org/10.3389/fcell.2022.921958 |
